articleLung CancerJul 24, 2017Closed access

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

SDStefan DiemSSSabine SchmidMKM. KrapfLFLukas FlatzDBDiana Born

University of St.Gallen · University of Bern · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,016
total citations
FWCI
28.74
Percentile
100%
References
41
Citations per year

Authors

8

Topics & keywords

Topics
Keywords
  • Medicine
  • Nivolumab
  • Lymphocyte
  • Neutrophil to lymphocyte ratio
  • Lung cancer
  • Platelet
  • non-small cell lung cancer (NSCLC)
  • Immunology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.